0001179110-17-011284.txt : 20170809 0001179110-17-011284.hdr.sgml : 20170809 20170809163201 ACCESSION NUMBER: 0001179110-17-011284 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170808 FILED AS OF DATE: 20170809 DATE AS OF CHANGE: 20170809 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kumar Ravindra CENTRAL INDEX KEY: 0001586835 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 171018358 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2017-08-08 0 0001280600 ACCELERON PHARMA INC XLRN 0001586835 Kumar Ravindra 128 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 SVP & Chief Scientific Officer Common Stock 2017-08-08 4 M 0 13065 24.11 A 108392 D Common Stock 2017-08-08 4 S 0 13065 35.41 D 95327 D Option to Purchase Common Stock 24.11 2017-08-08 4 M 0 13065 0 D 2023-12-05 Common Stock 13065 3624 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $35.84 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant. /s/ John D. Quisel, as attorney-in-fact for Ravindra Kumar 2017-08-09